Quarterly report pursuant to Section 13 or 15(d)

Statement of Cash Flows

Statement of Cash Flows
6 Months Ended
Jun. 30, 2016
USD ($)
Cash Flows From Operating Activities:  
Net loss $ (1,070,968)
Adjustments to reconcile net loss to net cash used in operating activities:  
Depreciation 652
Stock-based compensation 161,496
Changes in operating assets and liabilities:  
Prepaid expenses (315,143)
Accounts payable and accrued expenses (421,938)
Net Cash Used In Operating Activities (1,645,901)
Cash Flows From Investing Activities:  
Cash acquired through acquisition of Moleculin, LLC 362
Net Cash Provided By Investing Activities 362
Cash Flows From Financing Activities:  
Proceeds from notes payable 165,000
Payments on notes payable (469,939)
Proceeds from sale of common stock, net of direct offering costs 9,167,071
Net Cash Provided By Financing Activities 8,862,132
Net change in cash and cash equivalents 7,216,593
Cash and cash equivalents, at beginning of period 28,091
Cash and cash equivalents, at end of period 7,244,684
Supplemental disclosures of cash flow information:  
Cash paid for interest 47,951
Cash paid for income taxes 0
Supplemental disclosure of non-cash investing and financing activities:  
Assumption of accounts payable related to acquisition of Moleculin, LLC 100,000
Common stock issued to acquire Moleculin, LLC 9,773,586
Common stock issued for conversion of debt $ 201,055